Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 6/2020

Open Access 01-06-2020 | Computed Tomography | Original Article

Role of FDG-PET/CT in children with fever of unknown origin

Authors: Jordy P. Pijl, Thomas C. Kwee, G.E. Legger, Helja J.H. Peters, Wineke Armbrust, E.H. Schölvinck, Andor W.J.M. Glaudemans

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2020

Login to get access

Abstract

Purpose

To determine the role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) in children with fever of unknown origin (FUO).

Methods

This retrospective single-center study included 110 children (0–18 years) with FUO who underwent FDG-PET/CT between 2010 and 2019. The diagnostic value of FDG-PET/CT for identifying cause of fever was calculated, treatment modifications after FDG-PET/CT were assessed, and logistic regression analyses were performed to identify clinical and biochemical factors associated with FDG-PET/CT outcome.

Results

In 53 out of 110 patients (48%), FDG-PET/CT identified a (true positive) cause of fever. Endocarditis (11%), systemic juvenile idiopathic arthritis (5%), and inflammatory bowel disorder (5%) were the most common causes of FUO. In 42 patients (38%), no cause of fever was found on FDG-PET/CT. In 58 out of 110 patients (53%), treatment modifications were made after FDG-PET/CT. FDG-PET/CT achieved a sensitivity of 85.5%, specificity of 79.2%, positive predictive value of 84.1%, and negative predictive value of 80.9%. On multivariate logistic regression, C-reactive protein was positively associated with finding a true positive focus of fever on FDG-PET/CT (OR = 1.01 (95% CI 1.00–1.02) per mg/L increase in CRP), while leukocyte count was negatively associated with finding a true positive focus of fever (OR = 0.91 (95% CI 0.85–0.97) per 109 leukocytes/L increase).

Conclusion

FDG-PET/CT is a valuable diagnostic tool in the evaluation of children with FUO, since it may detect a true underlying cause in almost half (48%) of all cases where none was found otherwise. It allows full-body evaluation in patients without disease-specific symptoms on one examination. CRP and leukocyte count were significantly associated with FDG-PET/CT results, which may contribute to a priori assessment on the outcome of FDG-PET/CT. Future research could be aimed at evaluating more patient-specific factors to prospectively estimate the added value of FDG-PET/CT in children with FUO.
Literature
1.
2.
Brewis EG. Undiagnosed fever. Br Med J. BMJ Publishing Group; 1965;1: 107.
3.
Finkelstein JA E al. Fever in pediatric primary care: occurrence, management, and outcomes. Pediatrics. 2000 Jan;105(1 Pt 3):260–266.
4.
Nelson DS E al. Spectrum and frequency of pediatric illness presenting to a general community hospital emergency department. Pediatrics. 1992 Jul;90(1 Pt 1):5–10.
5.
Krauss BS E al. The spectrum and frequency of illness presenting to a pediatric emergency department. Pediatr Emerg Care 1991 Apr;7(2):67–71.
6.
Chow A, Robinson JL. Fever of unknown origin in children: a systematic review. World J Pediatr. SP Children’s Hospital, Zhejiang University School of Medicine; 2011;7: 5–10.
7.
Antoon JW E al. Etiology and resource use of fever of unknown origin in hospitalized children. Hosp Pediatr 2018 Mar;8(3):135–140.
8.
Greenes DS, Harper MB. Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatr Infect Dis J. 1999 Mar;18(3):258–61.CrossRef
9.
Cherry JD, Harrison GJ, Kaplan SL, Hotez PJ, Steinbach WJ. Feigin and Cherry’s textbook of pediatric infectious diseases. 7th edition, p840.
10.
Fusco FM, Pisapia R, Nardiello S, et al. Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review. BMC infec Dis. 2019;19:653.CrossRef
11.
Arnow PM, Flaherty JP. Fever of unknown origin. Lancet. 1997 Aug 23;350(9077):575–80.CrossRef
12.
Balink H, Verberne HJ, Bennink RJ, et al. A rationale for the use of F18-FDG PET/CT in fever and inflammation of unknown origin. Int J Mol Imaging. 2012;2012:165080.CrossRef
13.
14.
Pedersen TI, Roed C, Knudsen LS, Loft A, Skinhoj P, Nielsen SD. Fever of unknown origin: a retrospective study of 52 cases with evaluation of the diagnostic utility of FDG-PET/CT. Scand J Infect Dis. 2012;44:18–23.CrossRef
15.
Manohar K, Mittal BR, Jain S, Sharma A, Kalra N, Bhattacharya A, et al. F-18 FDG-PET/CT in evaluation of patients with fever of unknown origin. Jpn J Radiol. 2013;31:320–7.CrossRef
16.
Crouzet J, Boudousq V, Lechiche C, Pouget JP, Kotzki PO, Collombier L, et al. Place of (18)F-FDG-PET with computed tomography in the diagnostic algorithm of patients with fever of unknown origin. Eur J Clin Microbiol Infect Dis. 2012;31:1727–33.CrossRef
17.
Balink H, Collins J, Bruyn G, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med. 2009;34:862–8.CrossRef
18.
Sheng J-F, Sheng Z-K, Shen X-M, Bi S, Li J-J, Sheng G-P, et al. Diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with fever of unknown origin. Eur J Intern Med. 2011;22:112–6.CrossRef
19.
Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med. 2008;49:1980–5.CrossRef
20.
Tokmak H, Ergonul O, Demirkol O, Cetiner M, Ferhanoglu B. Diagnostic contribution of (18)F-FDG-PET/CT in fever of unknown origin. Int J Infect Dis. 2014;19:53–8.CrossRef
21.
Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58.CrossRef
22.
Jasper N, Däbritz J, Frosch M, Loeffler M, Weckesser M, Foell D. Diagnostic value of [(18)F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation. Eur J Nucl Med Mol Imaging. 2010;37:136–45.CrossRef
23.
Blokhuis GJ, Bleeker-Rovers CP, Diender MG, Oyen WJG, Draaisma JMT, de Geus-Oei L-F. Diagnostic value of FDG-PET/(CT) in children with fever of unknown origin and unexplained fever during immune suppression. Eur J Nucl Med Mol Imaging. 2014;41:1916–23.CrossRef
24.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42: 328–354.
25.
Niederkohr R, Thompson H, Chiu E. FDG PET/CT for characterization of indeterminate lymphadenopathy: can PET feasibly function as a “metabolic biopsy.” J Nucl Med. Society of Nuclear Medicine; 2017;58: 571–571.
26.
Brandon D, Bonta D, Bartley S, Alazraki N. The role of FDG PET-CT in incidental lymphadenopathy. J Nucl Med. Society of Nuclear Medicine; 2012;53: 1450–1450.
27.
Gomes A, Glaudemans AWJM, Touw DJ, van Melle JP, Willems TP, et al. Diagnostic value of imaging in infective endocarditis: a systematic review. Lancet Infect Dis Elsevier. 2017;17:e1–e14.CrossRef
28.
Pijl JP, Glaudemans AWJM, Slart RHJA, Yakar D, Wouthuyzen-Bakker M, Kwee TC. FDG-PET/CT for detecting an infection focus in patients with bloodstream infection: factors affecting diagnostic yield. Clin Nucl Med. 2019;44:99–106.CrossRef
29.
Landry A, Docherty P, Ouellette S, Cartier LJ. Causes and outcomes of markedly elevated C-reactive protein levels. Can Fam Physician. College of Family Physicians of Canada; 2017;63: e316.
30.
31.
Liles WC, Starkebaum G, Dale DC. Neutropenia in systemic lupus erythematosus. Blood. 2004;104:2.CrossRef
32.
Meller J, Sahlmann C-O, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. Society of Nuclear Medicine; 2007;48: 35–45.
33.
Bleeker-Rovers C, Vos F, de Kleijn E, Mudde A, Dofferhoff T, Richter C, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine . 2007;86: 26–38.
Metadata
Title
Role of FDG-PET/CT in children with fever of unknown origin
Authors
Jordy P. Pijl
Thomas C. Kwee
G.E. Legger
Helja J.H. Peters
Wineke Armbrust
E.H. Schölvinck
Andor W.J.M. Glaudemans
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-020-04707-z

Other articles of this Issue 6/2020

European Journal of Nuclear Medicine and Molecular Imaging 6/2020 Go to the issue

Original Article

TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study

Original Article

Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study

Correction

Correction to: A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB

Original Article

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-l-tyrosine PET

Original Article

FDG-PET assessment and metabolic patterns in Lafora disease

Letter to the Editor

18F-FDG PET/CT and COVID-19